Evaluating the role of HR 3D-CBCT and squid 12® embolic agent in meningioma management: Insights from MRI modifications at follow-Up
- PMID: 40294816
- DOI: 10.1016/j.neurad.2025.101346
Evaluating the role of HR 3D-CBCT and squid 12® embolic agent in meningioma management: Insights from MRI modifications at follow-Up
Abstract
We report three cases of meningiomas treated with Squid 12® with their peculiar technical aspects. High-resolution 3D cone-beam CT angiography (HR 3D-CBCT) was used to evaluate the tumor's vascular anatomy and guide embolization, revealing pial arterial supplies not readily visible on standard angiography. Squid 12® achieved deep tumor penetration, abolishing contrast enhancement on immediate post-procedural MRI. Follow-up MRIs showed progressive tumor shrinkage, with peripheral ring enhancement and decreased edema. Tumor volume was reduced by approximately 50% at the 4-6 months follow-up, leading to a delay in SRS for further stabilization and clinical improvement in the symptomatic patients.
Keywords: EVOH; Endovascular treatment; High-resolution cone-beam CT; Meningioma embolization.
Copyright © 2025 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial or personal relationships that could be viewed as influencing the work reported in this paper.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
